

References

References

- Abe Y., Kawakami M., Kuroki M., Yamamoto T., Fujii M., Kobayashi H., Yaginuma T., and Kashii A. (1993):** Transient rise in serum interleukin 8 concentration during acute myocardial infarction. *Br. Heart J.*, Aug., 70 (2), 132.
- Aggarwal B.B., Kohr W.J., Hoss P.E., Moffet B., and Spence S.A. (1985):** Human TNF production, purification and characterization. *J. Biol. Chem.*, 266, 2345.
- Alnemri E.S., Livingston D.J., and Nicholson D.W. (1996):** Human ICF, CED3 protease nomenclature . *Cell*, 87 , 171 (letter).
- Ambrosini G., Adida C., and Altieri D.C. (1997):** A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. *Nat. Med.*, 3, 917.
- Ambrosini G., Adida C., Sirugo G., and Altieri D.C. (1998):** Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. *J. Biol. Chem.*, 273, 11177.
- Amundson S.A., Myers T.G., and Fornace A.J. (1998):** Roles for P53 in growth arrest and apoptotic putting on the brakes after genotoxic stress. *Oncogene*, 17, 3287.
- Anderlini P., Ghaddar H.M., Smith T.L., Kantarijian H.M., O'Briens, Keating M.J., and Estey E.H. (1996):** Factors predicting complete remission and subsequent disease free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first. *Leukemia*, 10, 954.
-

- Antoku K., Liu Z., and Johnson D.E. (1998):** IL-3 withdrawal activates a Crm A-insensitive poly (ADP- ribose) polymerase cleavage enzyme in factor-dependent myeloid progenitor cells. *Leukemia*, 12, 682.
- Archimbaud E., and Thomas X. (1998):** Thrombopoietic factors potentially useful in the treatment of acute leukemia. *Leukemia Res.*, 22, 1125.
- Arlin A.Z., Kempin S., and Mertelsmann R. (1984):** Primary therapy of acute promyelocytic leukemia, result of amsacrine and daunorubicin based therapy. *Blood*, 63, 211.
- Armitage R.J. (1994):** Tumor necrosis factor receptor superfamily members and their ligands . *Curr. Opin. Immunol.*, 6, 407.
- Armitage J.O., and Burns C.P. (1978):** Maintenance therapy of adult acute non-lymphoblastic leukemia, an argument against the need for central nervous system prophylaxis. *Cancer*, 41, 697.
- Bachman L., Ringden O., and Tollemar J. (1988):** An increase risk of relapse in cyclosporin treated compared with methotrexate treated patients. Long-Term follow up of a randomized trial. *Bone Marrow Transplant*, 3, 463.
- Badran A., Yoshida A., Wano Y., Mutoh M., Imamura S., Yamashita I., Tsutani H., Inuzuka M., and Ueda T. (2003):** Expression of the anti-apoptotic gene survivin in myelodysplastic syndrome. *Int. J. Oncol.*, Jan; 22 (1) , 59.
- Bailly J.D., Skladanowski A., Bettaieb A., and Manasat V. (1997):** Natural resistance of acute myeloid leukemia cell lines to mitoxantrone is associated with lack of apoptosis. *Leukemia*, 11, 1523.
-

-
- Baraldi C.A., Beck A.C., and Rothstein G. (2000) :** Hematopoiesis and cytokines. Relevance to cancer and aging . Hematol. Oncol. Clin. North. Am., Feb, 14 (1), 45, Viii.
- Basanez G., Nechushtan A., and Drozhinin O. (1999):** Bax, but not Bcl-xL, decreases the life time of planar phospholipid bilayer membranes at subnanomolar concentrations. Proc. Natl. Acad. Sci, USA, 96, 5492.
- Baughman R.P., and Lower E.E. (1991):** An inhibitor of TNF found in pleural effusions. J. lab. Clin. Med., 118, 326.
- Bene M.C., Bernier M., Castoldi G., and Faure G. (1999):** Impact of immunophenotyping on management of acute leukemias. Haematologica, 84 (11), 1024.
- Bennett J.M., Catovsky D., and Daniel M.T. (1985):** Proposal revised criteria for the classification of acute myeloid leukemia. A report of the French- American-British group. Am. Intern. Med., 103 , 620.
- Bennett J.M., Catovsky D., and Daniel M.T. (1991):** Proposal for the recognition of minimally differentiated acute myeloid leukemia (AML-M0). Br. J. Haematol. 78, 325.
- Berger R., Bernheim A., and Daniel M.T. (1982):** Cytologic characterization and significance in t (8 ; 21) acute myeloid leukemia. Blood, 59, 171.
- Berman E., Little C., and Gec T. (1992):** Reasons that patients with acute myelogenous leukemia do not undergo allogenic bone marrow transplantation. N. EngL. J. Med., 326 , 156.
-

- Berman E., Raynond V., and Daghestani A. (1989):** 4-Demethoxy daunorubicine (Idarubicin) in combination with 1-Beta D-arabinofuranosylythosine in the treatment of relapsed or refractory acute leukemia. *Cancer Res.*, 49, 477.
- Bernard P., Lacombe F., and Reiffers J. (1985):** Relationship between patient's age, bone marrow karyotype and outcome of induction therapy in acute myelogenous leukemia. *Ann. J. Haematol.*, 18, 153.
- Bertino J.R. and Salmon S.E. (2000):** Principles of cancer therapy. In *Cecil Textbook of Medicine*, (eds.) by Goldman L. and Bennett J.C., W.B Saunders Company, a division of Harcourt Brace and Company. Philadelphia, London, Toronto, Sydney. 21st edition, chapter 198, page 1060.
- Bettes R., Rohatiner A.Z.S., and Evans M.L. (1992):** Abnormalities of chromosome 16q in myeloid malignancy, 14 new cases and a review of the literature. *Leukemia*, 6, (12), 1250.
- Beutler B. (1992):** Tumor necrosis factor; The molecules and their emerging role in medicine. *Science*, 183, 520.
- Beutler B., and Cerami A. (1989):** The biology of cachectin / TNF a primary mediator of the host response. *Annu. Rev. Immunol.*, 7, 625.
- Beutler B., and Van Huffel C. (1994):** Unraveling function in the TNF ligand and receptor families. *Science*, 264, 667.
- Beutler B., Mahoney J., Pakala P., and Cerami A. (1985):** Purification of cachectin, a lipoprotein-lipase suppressing hormone secreted by endotoxin included RAW 2647 cells. *J. Exp. Med.*, 161, 984.
-

- Beutler B., thompson P., Keyes J., and Hgerty K. (1988): Assay of a ribonuclease that preferentially hydrolysis mRNAs containing cytokine-derived UA-rich instability sequences. *Biochem. Biophys. Res. Commun.*, 152, 73.
- Biermer A. (1861): Ein fall von leukemia. *Virchows. Arch. Pathol. Anat.*, 20, 252.
- Bignold L., Rogers S., Siaw T., and Bahnisch J. (1992): Inhibition of chemotaxis of neutrophil leucocytes to IL-8 endotoxins of various bacteria. *Infect. Immunol*, 59, 4255.
- Bishop J.F., Lowenthal R.M., and Joshua D. (1990): Etoposide in acute non lymphocytic leukemia. *Blood*, 75, 27.
- Bishop J.F., Lowenthal R.M., and Joshua D. (1991): Etoposide in leukemia. *Cancer*, 67, 285.
- Bishop J.E., Young G.A., and Szer J. (1992): Randomized trial of high dose cytosine arabinoside (Arac-C) combination in induction of acute myeloid leukemia. *Proc. An. Soc. Clin. Oncol.*, 11, 849.
- Blaise D., Maraninchi D., and Archimbaude E. (1992): Allogenic bone marrow transplantation for acute myeloid leukemia in first remission, a randomized trial of a busulfan-cytosan versus cytosan-total body irradiation as preparative regimen, a report from the Grouped "Etudes dela Greffe de Moelle Osseuse ". *Blood*, 326, 156.
- Boayue K.B., Gu L., Yeager A.M., Kreitman R.J., and Findley H.W. (1998): Pediatric acute myelogenous leukemia cells express IL-6 receptors and are sensitive to a recombinant IL-6 pseudomonas exotoxin . *Leukemia*, 12 , 182.
-

- Boekhorst P.A.W., Lowenberg B., Vankapel J., and Nooter K. (1995):** Multidrug resistant cells with high proliferative capacity determine to therapy in acute myeloid leukemia. *Leukemia*, 9, 1025.
- Boles J.M., Dutel J.L., and Briere J. (1984):** Acute renal failure caused by extreme hyperphosphatemia after chemotherapy of an acute lymphoblastic leukemia. *Cancer*, 53, 2425.
- Bradstock K., Matthews J., Benson E., Page F., and Bishon J. (1994):** Prognostic value of immunophenotyping in acute myeloid leukemia. *Blood*, 84, 1220.
- Brago E.A., Marshall R.B., and Riberi A.M. (1977):** Preleukemic granulocytic sarcoma of the gastrointestinal tract. *Am. J. Clin. Pathol.*, 68, 616.
- Brakman P., Snyder J., and Henderson E.S. (1970):** Blood coagulation and fibrinolysis in acute leukemia. *British. J. Haematol.*, 18, 135.
- Brennan J.K., Dippersio J.F., and Abboud C.N. (1979):** The exceptional responsiveness of certain leukemia cells to colony stimulating activity. *Blood*, 7, 1230.
- Brenner B., Nagler A., and Tatarsky I. (1988):** Splenectomy in agnogenic myeloid metaplasia and post-polycythaemic myeloid metaplasia. A study of 34 cases. *Arch. Intern. Med.*, 148, 2501.
- Bruserud O., and Ulvestad E. (2000):** Soluble Fas/Apo-1 (CD 95) levels during cell activation in the presence of acute myelogenous leukemia accessory cells; contributions from local release and variation in systemic levels. *Cancer. Immunol. Immunotherapy*, Sep., 49 (7), 377.
-

- Bruserud O., Aasen I., Akselen P.E., and Bergheim J. (1996):**
Interleukin 1 receptor antagonist (IL-1 RA) in acute leukemia:
IL-1 RA is both secreted spontaneously by myelogenous leukemia
blasts and is a part of the acute phase reaction in patients with
chemotherapy-induced leucopenia. *Eur. J. Hematol.*, Jul., 57 (1),
87.
- Bruserud O., Akselen P.E., Bergheim J., and Nesthus I. (1995):**
Serum concentration of E-selectin, P-selectin, ICAM-1, and IL-6 in
acute leukemia patients with chemotherapy-induced leucopenia and
bacterial infections. *Br. J. Hematol.*, Oct., 91 (2), 394.
- Bruserud O., Mentzoni L., Buhning H.J., and Pawelec G. (1996) :**
Effects of hematopoietic growth factors on interleukin 6 secretion by
blast cells derived from AML patients. *Acta. Haematol.*, 96 (3), 155.
- Buchem M.A., Velde J., Willemze R., and Spaander P.J. (1988):**
Leukostasis an underestimated cause of death in leukemia. *Blute*,
56, 39.
- Buchner T., Hiddemann W., and Schaffer U.W. (1992):** Combined
effect of very early intensification and prolonged post-remission
chemotherapy in patients with AML. *Leukemia*, 5 (supple 14), 68.
- Budd D., and Ginsberg H. (1986):** Hypocholesterolemia and acute
myelogenous leukemia. *Cancer*, 58, 1361.
- Burger R., Bernheim A., and Weh H. (1980):** Cytogenetic studies on
acute monocytic leukemia. *Leukemia Res.*, 4, 119.
- Burnett A.K. (2001):** Treatment of acute myeloid leukemia in younger
patients. *Best. Pract. Res. Clin. Haematol*, March, 14 (1), 95.
-

- Burnett A.K., Goldstone A.H., and Stevens R.F. (1995):** The role of BMT in addition to intensive chemotherapy in AML in first CR, results of the MRC-AML-10 trial. *Blood*, 84, 10 (supple 1), 252a .
- Burns C.L., Armitage J.O., Frey A.L., Dick F.R., Jordan J.F., and Woolson R.F. (1981):** Analysis of the presenting features of adult acute leukemia. *Cancer*, 47, 2490.
- Cantor K.P., Blair A., and Everitt G. (1988):** Hair dye use and risk of leukemia and lymphoma. *Am. J. Public Health*, 78, 570.
- Capizzi R.L., Davis R., and Powell B. (1988):** Synergy between high dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia. Cancer and leukemia Group B. study. *J. Clin. Oncol.*, 6, 499.
- Capizzi R.L., Powell B.L., and Cooper R.M. (1985):** Sequential high dose Ara C and asparaginase in the therapy of previously treated and untreated patients with acute leukemia. *Semin Oncol*, 12 , 105.
- Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., and Williamson B. (1972):** An endotoxin induced serum factor that causes necrosis of tumor. *Proc. Natl. Acad. Sci. USA*, 72, 3666.
- Carter A., Huhad N., Droxler I., and Rowe J.M. (1996):** Expression and role in growth regulation of tumor necrosis factor receptors P55 and P75 in acute myeloblastic leukemia cells. *Br. J. Haematol*, 92 , 116.
- Carter M., Kalwinsky D.K., and Dahl G.V.C. (1989):** Childhood acute promyelocytic leukemia. A rare variant nonlymphoid leukemia with distinctive clinical and biological features. *Leukemia*, 3, 298.
-

- Cassileth P.A., Harring D.P., and Hines J.D. (1988):** Maintenance chemotherapy prolongs remission duration in adult acute non-lymphocytic leukemia. *J. Clin. Oncol.*, 6, 583.
- Cersosimo R.J. (1992):** Idarubicin; an anthracycline anti-neoplastic agent. *Clin. Pharm.*, 11, 152.
- Champlin R.E., and Gale R.P. (1987):** Acute myelogenous leukemia. Recent advances in therapy. *Blood*, 69, 1551.
- Champlin R.E., Gajewski J.L., and Nimer S. (1990):** Post-remission chemotherapy for adults with acute myelogenous leukemia. Improved survival with high dose cytarabine and daunorubicin as consolidation treatment. *J. Clin. Oncol.*, 8, 1199.
- Chandler J.M., Alnemri E.S., and Cohen M. (1997):** Activation of CPP32 and Mchz alpha in wild type P53-induced apoptosis. *Biochem. J.*, 322, 19.
- Chang K.S., Strass S.A., and Chu D.T. (1992):** Characterization of a fusion cDNA (RARA/myl) transcribed from t (15 ; 17) translocation break point in acute promyelocytic leukemia. *Mol. Cell Biol.*, 12, 800.
- Chaudhary D., O'Rourke K., Chinnaiyan A.M., and Dixit V.M. (1998):** The death inhibitory molecules CED-9 and CED-4 L use a common mechanism to inhibit the CED-3 death process. *J. Biol. Chem.*, 273, 17708.
- Childs C.C., Stass S.A., and Bennett J.M. (1986):** The morphologic classification of acute lymphoblastic leukemia in childhood; observations on concordance utilizing a simple scoring system. *Am. J. Clin. Pathol.*, 86, 503.
-

References

- Chillar R.K., Belman M.J., and Farbstein M. (1980):** Explanation for apparent hypoxaemia associated with the retinoic acid receptor alpha gene to a novel transcribed locus. *Nature*, 347, 558.
- Chinnaiyan A.M., O'Rourke K., Tewari M., and Dixit V.M. (1995):** FADD, a novel death domain containing protein, interacts with the death domain of Fas and initiate apoptosis. *Cell*, 81, 505.
- Chojnowski K., Wawrzyniak E., Trelinski J., and Niewiarowska J. (1999):** Assessment of coagulation disorders in patients with acute leukemia before and after cytostatic treatment. *Leuk-Lymphoma*, Dec., 36, (1-2), 77 (abst.).
- Chomienne C., and Daniel M.T. (1990):** The t (15 ; 17) translocation of acute myeloid leukemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. *Nature*, 347, 558.
- Cohen P.R., Talpaz M., and Kurzock R. (1988):** Malignancy associated Sweet's syndrome; review of the world literature. *J. Clin. Oncol*, 6, 1887.
- Coltman C.A., and Dixan D.O. (1982):** Second malignancies complicating Hodgkin's disease, a south west oncology group. 10 years follow up. *Cancer Treat. Rep.*, 66, 1023.
- Cooper R., Gordon M., and Weber J. (1993):** The in vivo administration of recombinant human IL-6 to patients with advanced malignancies has a profound effect on hematopoiesis. *Exp. Hematol*, 21, 1117.
- Cortes J., O'Brien S., Estey E., and Giles F. (1999):** Phase I study of liposomal daunorubicin in patients with acute leukemia. *Invest. New. Drugs*, 17 (1), 81.
-

- Crisan D. (2000):** Molecular mechanisms in myelodysplastic syndromes and implications for evolution to acute leukemia. *Clin. Lab. Med.*, 20 (1), 49.
- Crowe P.D., Van Arsdale T.L., and Walter B.N. (1994):** A lymphotoxin beta specific receptor. *science*, 264, 707.
- Dacie J. and Lewis S. (1975):** Bone marrow biopsy. In *Practical Haematology*.(eds.) by Dacie J. and Lewis S., Churchill livingstone, Edinburgh, London, New York. 5th edition, chapter 6, page 175.
- Dalton W.S., Cress A.W., and Alberats D.S. (1988):** Cytogenic amplification in promyelocytic leukemia cell line resistant to mitoxantrone. *Cancer Res.*, 48, 1882.
- Dann E.J., and Rowe J.M. (2001):** Biology and therapy of secondary leukemia. *Best. Pract. Res. Clin. Haematol.*, March, 14 (1), 119.
- Darby S.C., Doll R., Gill S.K., and Smith P.G. (1987):** Long-term mortality after a single treatment course with X-Ray in patients treated for ankylosing spondylitis. *Br. J. Cancer*, 55, 179.
- Davenpart R., Strieter P., Standiford T., and Kunkel S. (1991):** IL-8 production in red blood cell incompatibility. *blood*, 76, 2439.
- Dawson M.M. (1991):** Tumor necrosis factor. In *Lymphokines and Interleukines*. CRC Press Inc. Boca. Raton. Florida, 1st edition, chapter 10, page 210.
- De Bont E.S., Vellenga E., Molema G., Van Wering E., and de Leiji L.F.(2001):** A possible role for spontaneous interleukin 8 production by acute myeloid leukemia cells in angiogenesis related process; Work in progress. *Med. Pediatr. Oncol.*, Dec; 37 (6), 511.
-

- Dennis A.C., and Barry B.L. (2000):** Cancer chemotherapeutic agents. In *Manual of Clinical Oncology*, (eds.) by Dennis A.C. and Barry B.L., Lippincott Williams and Wilkins., Philadelphia, 4th edition, part I, chapter 4, page 92.
- Depraeter S., Vanhaesebroeck B., Fiers W., Willems J., and Marcel J. (1995):** Polar agents with differentiation inducing capacity potentiate tumor necrosis factor mediated cytotoxicity in human myeloid cell lines. *J. Leukoc. Biol.*, 57, 141.
- Dhaliwal H.S., Shannan M.S., and Barnett M.J. (1986):** Treatment of acute leukemia with m-AMSA in combination with cytosine arabinoside. *Cancer Chemother. Pharmacol.*, 18, 59.
- Dini G., Cancedda R., Locatelli F., Bosi A., Bandini G., Alessandrino E.P., and Porta F. (2001):** Unrelated donor marrow transplantation; an update of the experience of the Italian Bone Marrow Group (GITMO). *Haematologica*, May, 86 (5), 451.
- Doroshov J.H. (1983):** Anthracycline antibiotic stimulated superoxide peroxide, and hydroxyl radical production by NADH dehydrogenase. *Cancer Res.*, 43, 4543.
- Ellis H.M., and Horvitz H.R. (1986):** Genetic control of programmed cell death in the nematode *C. elegans*. *Cell*, 44, 817.
- Ellison R.R. (1982):** Acute myelocytic leukemia. In *Cancer Medicine* (eds.) by Holland J.F. and Frei E., Philadelphia, Lea, and Febiger, III, page 107.
- Enari M., Sakahira H., Yokoyama H., and Okawa K. (1998):** A caspase, activated DNase that degrades DNA during apoptosis and its inhibitor ICAD. *Nature*, 391, 43.
-

- Engel P., Francis D., and Graem N. (1998) :** Expression of BcL-2 in fetal thymus, thymomas and thymic carcinomas, association with P53 expression and review of the literature. *Apmis*, 106, 449.
- Engelmann H., Novick D., and Waallch D. (1990):** Two TNF-binding proteins purified from human urine. *J. Biol. Chem.*, 265, 1531.
- Eridani S., Pearson T.C., and Slater NGP. (1984):** A pilot study of epidoxorubicin (NSL 256942) in combination treatment of acute leukemia and non-hodgkin's lymphoma. *Oncology*, 41, 383.
- Estey E. (1996):** Treatment of refractory AML. *Leukemia*, 10, 932.
- Estey E., Thall P., and Andreeff M. (1994):** Use of granulocytic colony stimulating factor before, during, and after flaudarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. Comparison with flaudarabine plus cytarabine without granulocyte colony stimulating factor. *J. Clin. Oncol.*, 12 , 671.
- Ewback D. and Wray J. (1980):** Population and public health. In Maxcy-Rosenau; Public Health and Preventive Medicine textbook. (eds.) by John M., Philip E., James C., and Irving J. Appleton-Century-Crofts; New York, 11th edition, chapter 45, page 1504.
- Farhad R., Hagop M.K., Moshe T., Susan O., Stefan F., and Francis J. (2001):** Expression of apoptosis proteins in chronic myelogenous leukemia. *Cancer*, 91, 1964.
- Fearon E.R., Burk P.J., and Schiffer C.A. (1986):** Differentiation of leukemia cells to polymorphnuclear leucocytes in patients with acute non-lymphocytic leukemia. *N. Engl. J. Med.*, 315, 15.
-

References

- Feldman M. (1996):** Cytokines. *Immunology Today*, Jun, (3), 11. 8.
- Feliu J., Juarez S., and Ordonez A. (1988):** Acute leukemia and pregnancy. *cancer*, 61, 580.
- Ferlini C., De Angelis C., and Biselli R. (1999):** Sequence of metabolic changes during X-Ray induced apoptosis. *Exp. Cell Res.*, 247, 160.
- Fialkow P.J. (1977):** Use of genetic marker to study cellular origin in development of tumors in human females. *Adv. Cancer Res.*, 15, 191.
- Fialkow P.J., Singer J.W., and Adamson J.W. (1981):** Acute non-lymphocytic leukemia, Heterogeneity of stem cell origin. *Blood*, 57, 1068.
- Fialkow P.J., Singer J.W., and Raskind W.H. (1987):** Clonal development stem cell differentiation and clinical remissions in acute non-lymphocytic leukemia. *N. Engl. J. Med.*, 317, 468.
- Flandrin G., Brouet J.C., and Daniel M.T. (1975):** Acute leukemia with Burkitt's tumor cell. *Blood*, 45, 183.
- Foley N.M., Mc Nicol M.W., Rook G., and Johnson N. (1989):** Effects of serum from patients with sarcoidosis and tuberculosis on TNF-induced killing of murin cells. *Am. Rev. Respir. Dis.*, 139, A 58.
- Forman S.J., Schmidt G.M., and Nademanee A.P. (1991):** Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia. *J. Clin. Oncol.*, 9, 1570.
-

- Foucar A., Foucar E., and Willman C. (1987):** Non leukemic granulocytic sarcoma of the heart. A report of a fatal Case. *Am. J. Haematol.*, 25, 325.
- Frame R., Head D., and Lee R. (1987):** Granulocytic sarcoma of the prostate. *Cancer*, 59, 142.
- Frasconi F., Labopin M., and Glukman E. (1994):** Are patients with acute leukemia alive and well 2 years post bone marrow transplantation cured ? A European survey. *Leukemia*, 8, 949.
- Frederick R.A. (2000):** The acute leukemia. In *Cecil Textbook of Medicine*, (eds.) by Goldman L. and Bennett J.C., W.B Saunders Company, a division of Harcourt Brace and Company. Philadelphia, London, Toronto, Sydney. 21st edition , chapter 177, page 953.
- Freemont P.S. (2000):** RING for destruction ? *Curr0. Biol.*, 10, R 84.
- Friedman G.B. (1982):** Phenylbutazone, musculoskeletal disease and leukemia. *J. Chronic Disease*, 34, 233.
- Funch S.C., Hoshinton T., and Itogal T. (1969):** Chronic lymphocytic leukemia in Hiroshima and Nagasaki , Japan. *Blood*, 33, 78.
- Gale P., and Ben Bassat I. (1987):** Hybrid acute leukemia. *Br. J. Haematol.*, 65, 261.
- Gale P., and Foon K.A. (1986):** Acute myelogenous leukemia. In *leukemia therapy* (edits) by Robert Peter Gale. Blackwell Scientific Publication, Buston, page 99.
- Ganick D.J. (1986):** Haematological changes in Down's syndrome. *CRC-Crit. Rev. Onciol. Haematol.*, 6, 55.
-

References

- Gao J., Kuhns D., and Tifanny H. (1993): Structure and functional expression of the human macrophage inflammatory protein-1 alpha. *J. Exp. Med.*, 177, 1421.
- Gao X.Z., Bi S., Copra H., Devemy E., Li B., and Preisler H.D. (1998): Cytokine gene activity in AML cells in vivo inpatients. *Leuk. Res.*, May, 22 (5), 429.
- Garfinkel L., and Boffetta A. (1990): Association between smoking and leukemia in two American cancer society prospective studies. *Cancer*, 65, 2356.
- Garrido S.M., Cooper J.J., Appelbaum F.R., Willman C.L., Kopecky K., and Banker D.E. (2001): Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture and drug induced apoptosis. *Leuk. Res.*, Jan., 25 (1), 23.
- Giralt S., Escuder S., and Kantarijian H. (1993): Preliminary results of treatment with filgrastin for relapse of leukemia and myelodysplasia after allogenic bone marrow transplantation. *N. Engl. J. Med.*, 329, 757.
- Glassman A.B. (2000): Chromosomal abnormalities in acute leukemia. *Clin. Lab. Med.*, Mar, 20 (1), 39 "abst."
- Goasguen J.A., Bennett J.M., and Cox C. (1991): Prognostic implication and characterization of blast cell population in myelodysplastic syndrome. *Leuk. Res.*, 15, 1159.
- Goasguen J.A., Bennett J.M., and Henderson E.S. (1996): Biologic diagnosis of leukemia. In *Leukemia* (eds.) by Henderson E., Lister T.A. and Greaves M.F., W.B. Saunders company. Philadelphia, London, Toronto, Montreal, Sydney and Tokyo, chapter 1, page 8.
-

- Godder K.T., Metha J., Chiang K.Y., Adams S., Van-Rhee F., and Henslee Downey J.P. (2001):** Partially mis-matched related donor bone marrow transplantation as salvage for patients with AML who failed autologous stem cell transplant. *Bone Marrow Transplant*, Dec., 28 (11), 1031.
- Goh C.R. (1990):** Tumor necrosis factor in clinical practice. *Am. Acad. Med. Singapore*, 19, 235.
- Goldman J.M., Szydlo R., and Horowitz M.M. (1993):** Choice of pretransplant treatment and timing of transplant for chronic myelogenous leukemia in chronic phase. *Blood*, 82, 2235.
- Goldstein D., Wand A., and Glaspy J. (1990):** Therapeutic use of granulocyte and monocyte colony stimulating factors. In *Hematology* (eds.) by Williams W.J., Beulter E., Erlser A. and Lichtman M.A. Mc Graw-Hill-Inc. New York, St. Louis, San Francisco, chapter 16, page 154.
- Gollapudi L., and Oblinger M.M. (1999):** Stable transfection of PC12 cells with estrogen receptors (E R alpha). Protective effects of estrogen on cell survival after serum deprivation. *J. Neuro. Sci. Res.*, 56, 99.
- Gormley P.E., Sethi V.A., and Cysyk R.L. (1978):** Interaction of 4- (9-acridinylamino) methanesulfon-m-anisidide with DNA and inhibition of oncornavirus reverse transcriptase and cellular nucleic acid polymerase. *Cancer Res.*, 38, 1300.
- Greaves M.F. (1988):** Speculation on the cause of childhood acute lymphoblastic leukemia. *Leukemia*, 2, 120 .

- Green D.R., and Reed J.C. (1998):** Mitochondria and apoptosis. Science, 281, 1309.
- Greenberg B.R., Wilson F.D., and Wool (1981):** Cytogenic and granulopoietic effects of bone marrow fibroblastic cells in Fanconi's anemia. Br. J. Haematol, 48, 85.
- Gretzula J.C., Hevia O., and Weber P.J. (1987):** Bloom's syndrome. J. Am. Acad Derm., 17, 479.
- Griffin J.D., and Lowenberg B. (1986):** Clonogenic cells in acute myeloblastic leukemia. Blood, 68, 1185.
- Griffin J.D., Davis R., and Nelson D.A. (1986):** Use of surface markers analysis to predict outcome of adult acute myeloblastic leukemia. Blood, 68, 1232.
- Gross A., Yin X.M., and Wang K. (1999):** Caspase elevated Bid targets mitochondria and is required for cytochrome C release while Bcl-xl prevents this release but not tumor necrosis factor-R 1 / Fa death. J . Biol. Chem., 274,1156.
- Hacker M.P., Lazo J.S., and Tritton T.R. (1988):** Organ directed toxicities of anti-cancer drugs. The Hague. Matrinus Nijoff, 31.
- Hamza M.R.I., Gad Elmawla N.O., Hafez A.L.O., Kamel A.Z., Abdel Wareth A., Khaled H.M., Zikri K.Z., Elserafi M., and Elkhodary A. (1987):** Treatment of adult acute non-lymphocytic leukemia using combination chemotherapy regimens. J. of Egypt NCI, 3, 1, 71.
- Hanson C.A., Abaza M., and Sheldon S. (1993):** Acute biphenotypic leukemia, immunologic and cytogenic analysis. Br.J. Hematol,84,49.
-

- Hawley R.G. (1994):** Hematopathology of IL-6 cytokine. Stem cell Dayt, 12 (suppl) 1, 55.
- Head D.R. (1996):** Revised classification of acute myeloid leukemia. Leukemia, 10, 1826.
- Health C.W. (1982):** Leukemogenesis and low dose exposure to radiation and chemical agents. In Advances in comparative leukemia research (edits) by Yohn DS., and Plakeslee J.R., North Holland / Elsevier, Amsterdam, page 23.
- Hebert C., Luscinskas F., and Kiely J. (1990):** Endothelial and Leucocyte Forms of IL-8 conversion by thrombin and interactions with neutrophils. J. Immunol., 145, 3033.
- Helle M., Boeije L., and Aardan L. (1991):** ELISA for IL-6 in serum and synovial fluid. J. Immunol. Methods. 138, 47.
- Hempelmann L.H., Hall W.J., and Phillips M. (1975):** Neoplasms in persons treated with X-Ray in infancy. Fourth Survey in 20 years. J. Natl. Cancer. Inst., 55, 519.
- Henderson E. (1969):** Krankheitsverlauf für behandelte und unbehandelte unreife Leukämie im Erwachsenenalter. Haematol. Bluttransfus, 8, 89.
- Henderson I.C., Allegra J.C., and Woodcock T. (1989):** Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J. Clin. Oncol., 7, 560.
- Herzig R.H., Wolff S.N., and Lazarus H.M. (1983):** High dose cytosine arabinoside therapy for refractory leukemia. Blood, 62, 361.
-

- Hiddemann W., Kreutzmann H., and Straif K. (1987):** High dose cytosine arabinoside and mitoxantrone, a highly effective regimen in refractory acute myeloid leukemia. *Blood*, 69, 744.
- Ho A.D., Brado B., and Haas R. (1991):** Etoposide in acute leukemia. Past experience and future perspectives. *Cancer*, 67, 281.
- Hoelzer D. (1996):** Acute leukemias in adults. In *Oxford textbook of Oncology* (eds.) by Peckham M., Pinedo H., Umberto V. and Wagstaff J., Oxford University press. Oxford, New York , and Tokyo, page 1608.
- Hofmann K., Bucher P., and Tachopp J. (1997):** The CARD domain; a new apoptotic signaling motif . *Trends Biochem. Sci.*, 22, 155.
- Hou L., Zhai M., and Lu H. (1998):** Secretive activity of tumor necrosis factor alpha (TNF alpha) of marrow stromal cells in acute leukemia and its clinical significance. *Zhonghua - Xue - Ye - Xue - Za - Zhi*, 19 (7), 356.
- Howard S.F. (1996):** Cytokines and cell adhesion molecules. In *Clinical Diagnosis and Management by laboratory methods Textbook* (eds.) by Frederick RD., Robert M.N. and Matlthew RP. Philadelphia, London, Toronto, Montreal, Sydney and Tokyo. 9th edition. page 947.
- Hsu H.C., Lee Y.M., Tsai W.H., Jiang M.L., Ho C.H., and Wang S.Y. (2002):** Circulating levels of thrombopoietin and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome. *Oncology*, 63 (1), 64.
-

- Huang C., Deng M., and Guo R. (1987):** A study of the induction of differentiation of human leukemic cells by harringtonine combined with cytarabine. *Leukemia*, 69, 744.
- Ichinose Y., Tsao J.Y., and Fidler I.J. (1988):** Destruction of tumor cells by monokines released from activated human blood monocytes: evidence for parallel and additive effects of IL-1 and TNF. *Cancer Immunol. Immunother.*, 27, 7.
- Inaba H., Komada Y., Li Q.S., Zhang X.L., Tanaka S., Azuma E., Yamamoto H., and Sakurai M. (1999):** mRNA expression of variant Fas molecules in acute leukemia cells. *Am. J. Hematol.*, Nov; 62 (3), 150.
- Irmeler M., Thome M., and Hahne M. (1997):** Inhibition of death receptor signals by cellular FLIP. *Nature*, 388, 190.
- Jablonska E., Jablonski J., Holownia A., Iwaszkiewicz P.A., and Piotrowski L. (2001):** TNFRs and IL-6 R transmembrane receptors: expression and release of their soluble form by neutrophils and mononuclear cells from cancer patients. *Rocz. Akad. Med. Biolymski*; 46, 113.
- Jaccard J., and Becker M.A. (1997):** Statistics for the behavioral sciences. 3rd edition, ITP company.
- Jackson N., Menon B.S., Zarina W., Zawawi N., and Naing N.N. (1999):** Why is acute leukemia more common in males? Apoptosis: sex determined risk linked to the ABO blood group genes. *Ann. Haematol.*, May, 78, (5), 233.
- Jacobs A. (1989):** Benzene and leukemia. *Br. J. Haematol.*, 72, 119.
-

- Jensen A.K., and Killman S.A. (1971):** Additional incidence for chromosome abnormalities in the erythroid precursors in acute leukemia. *Acta. Med. Scand.*, 189, 97.
- Johanna S., and Jonas B. (2001):** How apoptosis is regulated and what genes wrong in cancer. *BMJ* , 322 (23), 1538.
- Johnson P.R., and Liu Yin J.A. (1993):** Clinical annotation: Acute myeloid leukemia in the elderly, Biology and treatment. *Br. J. Haematol*, 84, 37 “ abst.”.
- Jowitt S.N., Yin J.A.L., and Saunders M.J. (1993):** Relapsed myelodysplastic clone differs from acute onset clone as shown by X-linked DNA polymorphism patterns in patient with acute myeloid leukemia. *Blood*, 82, 613.
- Kahn S.B., Begg C.B., and Mazza J.J. (1986):** Therapy related leukemia and myelodysplastic syndrome. Clinical, cytogenetic and prognostic features. *J. Clin. Oncol*, 4, 1748.
- Kaiserling E., Horny H.P., and Geerts M.I. (1994):** Skin involvement in myelogenous leukemia. Morphologic and immunophenotypic heterogeneity of skin infiltrates. *Mod. Pathol.*, 7, 771.
- Kanayama N., Elmaradny E., and Halim A. (1995):** Urinary trypsin inhibitor suppresses premature cervical ripening. *Eur. J. Obst. Gynecol. Reprod. Biol.*, 60, 181.
- Kantarijian H.M. (1993):** Treatment of therapy related leukemia and myelodysplastic syndrome. *Haematology / oncology clinics of north America* , 7, 81.
-

- Kantarjian H.M., Keating M.J., and Walters R.S. (1986):** Therapy-related leukemia and myelodysplastic syndrome. Clinical, cytogenetic and prognostic features. *J. Clin. Oncol.*, 4, 1748.
- Karesh J.W., Goldman E.J., and Reck K. (1989):** A prospective ophthalmic evaluation of patients with acute myeloid leukemia, correlation of ocular and hematologic findings. *J. Clin. Oncol.*, 7, 1528.
- Kashiwagi A., Hanada H., and Yabuki M. (1999):** Thyroxin enhancement and the role of reactive oxygen species in tadpole tail apoptosis. *Free Rad. Biol. Med.*, 26, 1001.
- Katz J.A., Wagner M.L., and Gresik M.V. (1990):** Typhlitis. *Cancer*, 65, 1041.
- Keil E., Prinz E., Kalhs P., Lechner K., and Moser K. (2001):** Treatment of leukemic relapse after allogenic stem cell transplantation with cytoreductive chemotherapy and / or immunotherapy or second transplants. *Leukemia*, 15, 355.
- Keinanen M., Griffin J.D., and Bloomfield C.D. (1988):** Clonal chromosomal abnormalities showing multiple cell-Lineage involvement in acute myeloid leukemia. *N. Engl. J. Med.*, 318, 1153.
- Kelekar A., and Thompson C.B. (1998):** Bcl-2 Family proteins; the role of the BH3 domain in apoptosis. *Trends cell Biol.*, 8, 324.
- Kenneth A.F., and Dennis A. C. (2000):** Acute leukemia. In *Manual of Clinical Oncology*, (eds.) by Dennis A.C. and Barry B.L., Lippincott Williams and Wikins., Philadelphia, 4th edition, part III, chapter 25, page 506.
-

Kerr J.F., Wyllie A.H., and Currie A.R. (1972): Apoptosis, a basic biological phenomenon with wide ranging implications in tissue kinetics. *Br. J. Cancer*, 26, 239.

King A. (1853): A case of chloroma. *Monthly J. Med.*, 17, 97.

Koeppler H., Pflueger K.H., and Knapp W. (1987): Establishment of three permanent human leukemia cell lines producing immunoreactive calcitonin. *Br. J. Haematol.*, 65, 405.

Konopleva M., Zhao S., Hu W., Jiang S., Snell V., and Weidner D. (2002): The anti-apoptotic genes Bcl-xl and Bcl-2 are over-expressed and contribute to the chemo-resistance of non-proliferating leukemic CD34+ cells. *Br. J. Haematol.*, Aug; 118 (2), 521.

Korkolopolou P., Angelopolou M.K., Kontopidou F., and Tsenga A. (1998): Prognostic relevance of apoptotic cell death in non-hodgkin's lymphoma; A multivariate survival analysis including Ki 67 and P53 oncoprotein expression. *Histopathology*, 33 , 240.

Kriegler M., Perez C., Defay K., Albert I., and Lu S.D. (1988): A novel form of TNF/cachectin in a cell surface cytotoxic transmembrane protein, ramification for the complex physiology of TNF. *Cell*, 53, 45.

Kuriakose M.A., Chen F.A., Egilmez N.K., Jong Y.S., and Mathiowitz E. (2000): Interleukin-12 delivered by biodegradable microspheres promotes the anti-tumor activity of human peripheral blood lymphocytes in human head and neck tumor xenograft / SCID mouse model. *Head and Neck*, Jan., 22 (1), 57.

- Kurrie E., Bhaduri S., and Krieger D. (1981):** Risk for infections of the oropharynx and the respiratory tract in patients with acute leukemia. *J. Infect. Dis.*, 144, 128.
- Kurzrock R. (1997):** Cytokine deregulation in haematological malignancies. Clinical and biological implications. *Clin. Cancer. Res.*, Dec., 3, (12 pt 2); 2581.
- Lambertenghi D.G., Annaloro C., and Oriani A. (1993):** Prognostic relevance of histological findings on bone marrow biopsy in myelodysplastic syndrome. *Ann. Haematol.*, 66, 85.
- Lanza F., Castagnari B., Rigolin G., Moretti S., and Latoroca A. (1997):** Flow cytometry measurement of GM-CSF receptors in acute leukemic blasts and normal haematopoietic cells. *Leukemia*, 11, 1700.
- Laterverr L., Lindley I., and Heemskerk D. (1996):** Rapid mobilization of hematopoietic progenitor cells in rhesus monkeys by a single intravenous injection of IL-8. *Blood*, 87, 781.
- Lee E.J., Pollak A., and Leavitt R.D. (1987):** Minimally differentiated acute non-lymphocytic leukemia. A distinct entity. *Blood*, 70, 1400.
- Lee E.J., Yang J., Leavitt R.d., Civin C.I., and Schiffer G.A. (1992):** The impact of TdT and CD34 expression on the prognosis of patients with acute myeloid leukemia. *Leukemia*, 6, 1203.
- Lennert K., and Parwaresch M.R. (1979):** Mast cells and mast cells neoplasia. A review *Histopathology*, 3, 349.
-

-
- Levine E.G., and Bloomfield C.D. (1992):** Leukemia and myelodysplastic syndromes secondary to drug, radiation and environmental exposure. *Semin Oncol*, 19, 47.
- Liam M.T., Pszin G.J., and Armstrong J.A. (1981):** Herpes simplex infection in acute myelogenous leukemia and other haematologic malignancies . A prospective study. *Cancer*, 48, 2168.
- Lin J.D. (2001):** The role of apoptosis in autoimmune thyroid disorders and thyroid cancer. *B.M.J.*, 322, 23, Jun., 1525.
- Lindley I., Westwick J., and Kunkel S. (1993):** Nomenclature announcement the chemokines. *Immunology Today*, 14.
- Linnet M.S., and Devesa S.S. (1990):** Descriptive epidemiology of the leukemia. In *Leukemia* (eds) by Henderson E., Lister A., W.B. Saunders, Philadelphia, page 207.
- Liu J., Qi Z., Luo L., and Zhang X. (1999):** Measurement of soluble Fas in patients with hematological malignancy. *Human Yi Ke Da Xue Xue Bao.*, 24 (2), 171.
- Liu J., Wei S., Lamy T., Li Y., Epling-Burnette P., Djeu J.Y., and Loughran T.P. (2002):** Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia. *Blood*, Aug 15, 100 (4), 1449.
- Liu J., Zeng H., and Zhang Y. (1999):** Study on the expression of interleukin 8 and its receptors in acute leukemia. *Zhonghua Xue Ye Xue Za Zhi*, Jan, 20 (1), 24.
- Lotem J., and Sachs L. (1996):** Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes. *Leukemia*, Jun., 10 (6), 925.
-

- Lowenberg B. (2001):** Managing therapy in older adult patients with acute myeloid leukemia. *Semin. Hematol*, Jul., 38, (3 suppl 6), 10.
- Lowenberg B., and Burnette A.K. (1999):** Acute myeloid leukemia in adults. In *Text Book of Malignant Hematology* (eds.) by Degos L., Linch D. and Lowenberg B. page 743.
- Lukens J.N. (1993):** Classification and differentiation of the acute leukemia. In *Wintrob's Clinical Haematology* (eds) by Lee G.R., Bithell T., Foerster J., Athens J.W. and Lukens J.N. 9th edition, Lea and Febiger, Philadelphia, page 1873.
- Mac Callum P.K., Davis Cl.L., and Rohatiner A.Z.S. (1993):** Mitoxantrone and cytosine arabinoside as treatment for AML at first recurrence. *Leukemia*, 7 (10), 1496.
- Macnamara B., Paluka K.A., and Mac Donald P.A. (1999):** Balance between proliferation and apoptosis in leukemic cell lines resistant to cytostatics. *Leuk. Lymphoma*, Dec., 36, (1-2); 179 (abst.).
- Magnusson C., and Vaux D.L. (1999):** Signaling by CD95 and TNF receptors not only life and death. *Immunol., cell Biol.*, 77, 41.
- Mak N.K., Wong R.N., Leung K.N., and Fung M. (2002):** Involvement of tumor necrosis factor alpha in arsenic trioxide induced apoptotic cell death of murine myeloid leukemia cells. *Toxicol. Lett.*, Sep; 135 (1-2), 79.
- Malcolm K.B. (2000):** Stem cell transplantation. In *Cecil Textbook of Medicine*, (eds.) by Goldman L. and Bennett J.C., W.B Saunders Company, a division of Harcourt Brace and Company . Philadelphia, London, Toronto, Sydney. 21st edition , chapter 182, page 987.
-

- Mandelli F., and Montefusco E. (1999):** Treatment of acute and chronic leukemia. *Recenti. Prog. Med.*, 90, (11), 605.
- Maschek H., Katoutsis V., and Rodriguez M. (1993):** Hypoplastic myelodysplastic syndrome; incidence, morphology, cytogenetics and prognosis. *Ann. Hematol.*, 66, 117.
- Matsou T., Cox C., and Bennet J.M. (1989):** Prognostic significance of myeloperoxidase positivity of blast cells in acute myeloblastic leukemia without maturation (FAB-M1). An ECOG study. *Haematol. Pathol.*, 3, 153.
- Mayer R.J., Davis R.B., and Schiffer C.A. (1992):** Comparative evaluation of intensive post-remission therapy with different dose schedules of Ara C in adults with acute myeloid leukemia. Initial results of a CALGB phase II study. *Proc. Am. Soc. Clin. Oncol.*, 11, 853.
- Mayer R.J., Davis R.B., and Schiffer C.A. (1994):** Intensive post-remission chemotherapy in adults with acute myeloid leukemia. *N. Engl. J. Med.*, 331, 896.
- McKinney P.A., Alexander E.E., and Roberts B.E. (1990):** Yorkshire case-control study of leukemias and lymphomas. Parallel multivariate analysis of seven disease categories. *Leukemia and Lymphoma*, 2, 67.
- Medema J.P., Scaffidi C., and Kischkel F.C. (1997):** FLICE is activated by association with the CD95 death inducing signaling complex (DISC). *Embo. J.*, 16, 2794.
-

- Michael W., William J., and Douglas A. (1995):** Automated blood cell counting. In Williams Haematology Textbook. (eds.) by Ernest B., Marshal A., Barry S., and Thomas J. McGraw-Hill, Inc. Health professions Division. New York, St. Louis, San Francisco, London, Madrid, Mexico City, Milan, Montreal, Sydney, Tokyo, Toronto. 5th edition. Chapter L1, Page L3.
- Miller L.K. (1999):** An exegesis of IAPs; Salvation and surprises from BIR motifs. Trends cell Biol., 9, 323.
- Miller K.B., Grunwald H., and Preisler A. (1982):** A prognostic indicator for AML induction. The day 6 bone marrow aspirate and biopsy. Blood, 60, 156 a.
- Mizutani Y., Yoshida O., and Bonavida B. (1998):** Prognostic significance of soluble Fas in the serum of patients with bladder Cancer. J. Urol., 160 , 571.
- Modan B., Baidat Z.D., Hannah M., and Levin S.G. (1974):** Radiation induced head and neck tumors. Lancet, 1, 227.
- Morley A., and Higgs D. (1974):** Abnormal differentiation of leukemia cells in vitro. Cancer, 33, 716.
- Mosmann T. (1996):** Cytokines and immune regulation. In Clinical Immunology Principles and Practice, (eds.) by Rich R.R., Fleisher T.A. and Shearer W.T., Mosby St. Louis, Baltimore, Boston, Catlsbad, Chicagon Naples, New York , page 217.
- Muggia F.M., Heinermann H.O., and Farhani M. (1969):** Lysozymuria and renal tubular dysfunction in monocytic and myelomonocytic leukemia. Am. J. Med., 47, 351.
-

- Muller S., Sangster G., and Crocker J. (1986):** An immunohistochemical and clinicopathological study of granulocytic sarcoma (chloroma). *Hematol. Oncol.*, 4, 101.
- Munker R., Lubbert M., Yonehara S., Geley S., Kofler R., and Greil R. (1995):** Expression of the Fas antigen on primary human leukemia cells. *Ann. Haematol.*, 70, 15.
- Nagata S. (1997):** Apoptosis by death factor. *Cell*, 88, 355.
- Nagata S., and Goldstein P. (1995):** The Fas death factor. *Science*, 267, 1449.
- Nand S., and Godwin J.E. (1988) :** Hypoplastic myelodysplastic syndrome. *Cancer*, 62, 958.
- Neiman R.S., Balcos M., and Berard C. (1981):** Granulocytic sarcoma; A clinicopathological study of 61 biopsied cases. *Cancer*, 48, 1426.
- Nguyen D., and Imbert M. (1992):** Classification, morphology and cytochemistry of acute leukemia. In *Leukemia* (eds) by Wittaker J.A., 2nd edition, Blackwell Scientific Publication. London, page 173.
- Nukhet N. and John M. (1996):** Classification of acute leukemias: Cytochemical and Morphologic considerations. In *Neoplastic Diseases of the blood*. (eds.) by Peter H., George P., Janice P., and Robert A. 3rd edition. Churchill Livingstone. New York, Edinburgh, London, Madrid, Melbourne, San Francisco, Tokyo. Chapter 13, page 201.
- O'Connor R. (1998):** Survival factors and apoptosis. *Adv. Biochem. Eng. Biotechnol.*, 62, 137.
-

- O'Gorman D.M., and Cotter T.G. (2001):** Molecular signals in antiapoptotic survival pathways. *Leukemia*, 15, 21.
- Olie R.A., and Zangemeister W.U. (2001):** Targetting tumor cell resistance to apoptosis induction with antisense oligonucleotides; progress and therapeutic potential. *Drug-Resist. Update*, Feb., 4 (1), 9 .
- Oltvai Z., Milliman C.L., and Korsmeyer S. J. (1993):** Bcl-2 heterodimerizes in vivo with a conserved homology, Bax, that accelerates programmed cell death. *Cell*, 74, 609.
- Oppenheim J.J., Francis W.R., and Connei F. (1994):** Cytokines. In *Basic and Clinical Immunology*. (eds.) by Stites D.P. and Terr A.I., 8th edition, Appleton and Lange, page 105.
- Oppenheim J.J., Ruscetti F.W., and Fattynek C. (1991):** Cytokines. In *Basic and Clinical Immunology*, (eds.) by Stites D.P. and Terr AI. 7th edition, Appleton and Lange, page 78.
- Oppenheim J., Murphy W., Chertox O., and Wang J. (1997):** Prospects for cytokines and chemotone biotherapy. *Clin. Cancer Res.*, Dec., 3 (12 pt 2), 2682.
- Orazi A., Cattorett G., and Saligo D. (1993):** Therapy related myelodysplastic syndromes. FAB classification, bone marrow histology and immunohistology in the prognostic assessment. *Leukemia*, 7, 838.
- Otter I., Conus S., and Ravn U. (1998):** The binding properities and biological activities of Bcl-2 and Bax in cells exposed to apoptotic stimuli. *J. Biol. Chem.*, 273, 6110.
-

- Paciucci P.A., Dutcher J.P., and Cuttner J. (1987):** Mitoxantrone and Ara-C in previously treated patients with acute myelogenous leukemia. *Leukemia*, 1, 565.
- Parker F. (2000) :** Non metastatic effects of cancer “ the skin “. In Cecil Textbook of Medicine, (eds.) by Goldman L. and Bennett J.C., W.B Saunders Company, a division of Harcourt Brace and Company. Philadelphia, London, Toronto, Sydney. 21st edition , chapter 196, page 1057.
- Parton M., Dowsett M., and Smith I. (2001):** Studies of apoptosis in breast cancer. *BMJ*, Jun., 322, 1528.
- Pavlovsky S., Gonzalez L., Laven J., and Garcia Martinez M.A. (1994):** A randomized study of mitoxantrone plus cytarabine versus daunorubicin plus cytarabine in the treatment of previously untreated adult patients with acute non-lymphocytic leukemia. *Ann. Haematol.*, 69, 11.
- Pearson E.G. (1986):** Crystal structure of Auer rods in acute myeloblastic leukemia. *Clin. Pathol.*, 39, 569.
- Petersen F.B., Lynch M.H.E., and Clift R.A. (1993):** Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission. *J. Clin. Oncol.*, 11, 1353.
- Phillips G.L., Reece D.E., Shepherd J.D., Barnnett M.J, Brown R.A., and Freilahr D.A. (1991):** High dose cytarabine and daunorubicin induction and post-remission chemotherapy for the treatment of AML in adults. *Blood*, 77,1429.
-

- Pierri I., Clavio M., Beltrami C., and Cavaliere M. (1999): GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short and effective induction treatment for denovo AML, suitable for the elderly. *J. Exp. Clin. Cancer Res.*, 18 (1), 55.
- Pizzo P.A., Robichaud K.J., and Gill F.A. (1982): Empiric antibiotic and antigungal therapy for cancer patients with prolonged fever and granulocytopenia. *Am. J. Med.*, 72, 101.
- Plunkett W., Lillie mrk J.O., and Estey E. (1987): Saturation of Ara-CTP accumulation during high dose Ara-C Therapy. Pharmacologic rationale for intermediate dose Ara-C. *Semin Oncol*, XIV, (suppl 1), 159.
- Pothana S., Zheng D., Valery M., Michael D., and Jeel M. (1999): Apoptosis: Definition, mechanisms, and relevance to disease. *Am. J. Med.*, 107, 489.
- Priault M., Chaudhuri B., and Clow A. (1999): Investigation of Bax induced release of cytochrome C from yeast mitochondria permeability of mitochondrial membrane, role of VDAC and ATP requirement. *Eur. J. Biochem*, 260, 684.
- Priker R., Wallner J., and Geissler K. (1991): MDR1 gene expression and treatment outcome in acute myeloid leukemia. *J. Nat. cancer inst.*, 83, 708.
- Pui C., Behm F.G., and Singh B. (1990): Myeloid associated antigen expression in childhood lymphoblastic leukemia. *Blood*, 75, 198.
- Pui C., Campapa D., and Crist W.M. (1995): Towards a clinically useful classification of the acute leukemias. *Leukemia*, 9, 2147.
-

- Quesenberry P.J. (1995):** Hematopoietic stem cells, progenitor cells and cytokines. In Hematology (eds) by Williams J., Beutler E., Erslev A.J. and Lichtman M.A., MC Graw-Hill book company. Page 211.
- Ravandi F., Kantarjian H.M., Talpaz M., O'Brien S., and Thomas D. (2001):** Expression of apoptosis proteins in chronic myelogenous leukemia; associations and significance. *Cancer*, Jun 1, 91 (11), 1964.
- Reece D.E., Elmongy M.B., and Banett M.J. (1993):** Chemotherapy with high dose cytosine arabinoside and mitoxantrone for poor prognosis myeloid leukemia. *Cancer*, 11, 509.
- Reed J.C. (1998):** Bcl-2 family proteins. *Oncogene*, 17, 3225.
- Rees R. (1992):** Cytokine as biological response modifiers. *J. Clin. Pathol.*, 45, 93.
- Reuter C., Schleyer E., Rolf C., Wormann B., and Buchner T. (1997):** Differential effect of GM-CSF pretreatment on intracellular Ara-C metabolism in normal bone marrow mononuclear cells versus acute myeloid leukemia (AML) blasts. *Leukemia*, 11, 561.
- Reza S., Shetty V., Dar S., Qawi H., and Reza A. (1998):** Tumor necrosis factor alpha levels decreases with anti-cytokine therapy in patients with myelodysplastic syndrome. *J. Interferon. Cytokine Res.*, oct., 18 (10), 871.
- Richards C., Langdon C., Pennica O., and Gauldie J. (1996):** Murine cardiotrophin-1 stimulates the acute phase response in rat hepatocytes and H35 hepatoma cells. *J. Inter. Cytokine Res.*, 16, 69.
-

- Richard M.S., and Robert J.M. (1995):** Acute myeloid Leukemia in adults. In Clinical Oncology (eds.) by Martin D.A., James Q.A., Allen S.L. and John E.N. Churchill livingstone. New York, Edinburg, London, Melbourne, and Tokyo, page 1959.
- Ricki M.B. (1995) :** The dance of cell death. The Scientist , 9 (3) , 1.
- Ridgway E.W., Jaffe N., and Walton D.S. (1976):** Leukemia ophthalmopathy in children. Cancer, 38, 1744.
- Robison L.L., Buckely J.D., and Daigle A. (1989):** Maternal drug use and risk of childhood non-lymphoblastic leukemia among offspring. Cancer, 63, 1904.
- Robison L.L., and Neglia J.P. (1987):** Epidemiology of Down syndrome and childhood acute leukemia. In Oncology and Immunology of Down syndrome (eds.) by Mc Coy E.E. and Epstein C.J. Alan Liss, New York, page 19.
- Rodeghiero F., Arvisati G., and Castaman G. (1990):** Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. AGIMEMA retrospective study in 268 consecutive patients. Blood, 75, 2112.
- Rohatiner A., and Lister T.A. (1996):** Acute myelogenous leukemia in adults. In Leukemia (eds.) by Henderson E., Lister T.A. and Greeves M.F., W.B. Saunder company, a division of Har court Brace company. Philadelphia, London, Toronto, Montreal, Sydney and Tokyo, page 479.
- Roman J., Fernandez F., Velasco F., Rojas R., Roldan M.R., and Torres A. (1993):** Serum TNF levels in neonatal sepsis and septic shock. Acta. Pediatr. , 82, 352.
-

- Rosenbaum J.T., Howes E.L., Rulin R.M., and Samples J.R. (1988):** Ocular inflammatory effects of intravitreally-injected tissue necrosis factor. *Am. J. Pathol.*, 133, 47.
- Rosner F., Dobbs J.V., and Ritz N.D. (1970):** Disturbances of haemostasis in acute myeloblastic leukemia. *Acta. Haematologica*, 43, 65.
- Ross J.R.Y., and Gliber M.J. (1993):** Leukemia survival in an unselected cohort of patients. The Oxford region leukemia register. *Br. J. Haematol*, 83, 1.
- Rowe J.M. (1983):** Clinical and laboratory features of the myeloid and lymphoid leukemias. *Am. J. Med. Technol.*, 49, 103.
- Rowley J.D. (1973):** Identification of a translocation with Quinochorine fluorescence in a patient with acute leukemia. *Ann. Genet.*, 16, 109.
- Rubak T. (1996):** Cytokines in the treatment of hematological disorders; recent progress and perspective. *Ach. Immunol. Ther. Exp. Warsz*, 44 (1), 5.
- Ruoslahti E., and Reed J.C. (1994):** Anchorage dependence; integrins and apoptosis. *Cell*, 77, 477.
- Saikumar P., Dong Z., Weinberg J.M., and Venkatachalam M.A. (1998):** Mechanisms of cell death in hypoxia / reoxygenation injury. *Oncogene*, 17, 3341.
- Saily M., Koistinen P., Zheng A., and Savolainen E. (1998):** Signaling through IL-6 receptor supports blast cell proliferation in AML. *Eur. J. Haematol*, 61, 190.
-

- Sawitsky A., Blood D., and German J. (1966): Chromosomal breakage and acute leukemia in congenital telangiectatic erythema and stunted growth. *Ann. Intern. Med.*, 65, 487.
- Schall T.J., Lewis M., and Koller K.J. (1990): Molecular cloning and expression of a receptor for human TNF. *Cell Der. Biol.*, 61, 361.
- Schenkein D.P., O'Neill C., and Shapiro J. (1986): Acceleration bone formation causing profound hypercalcaemia in acute leukemia. *Ann. Intern. Med.*, 105, 375.
- Schiffer C.A., Lee E.J., and Tomiyasee T. (1989): Prognostic impact of cytogenetic abnormalities in patients with de novo acute non-lymphocytic leukemia. *Blood*, 73, 263.
- Schiller G., Gajewski J., and Territo M. (1992): Long-term outcome of high dose cytarabine based consolidation chemotherapy for adults with acute myelogenous leukemia. *Blood*, 80, 2977.
- Schiller G., Lee M., Miller T., Lill M., Mitta-Henkle A., Paquette R., Sawyers C., and Territo M. (1997): Transplantation of autologous peripheral blood progenitor cells procured after high dose cytarabine based consolidation therapy for adults with acute myelogenous leukemia in first remission. *Leukemia*, 11, 1533.
- Schimpff S.C. (1985): Overview of empiric antibiotic therapy for the febrile neutropenic patients. *Rev. Infect. Dis.*, 7, (suppl 4), 5734.
- Schonbohn H., Schuler M., Kolbe K., Peschol C., Huber C., and Bemb W. (1995): Plasma levels of IL-1, TNF alpha, IL-6, IL-8, G-CSF and IL-1RA during febrile neutropenia: results of a prospective study in patients undergoing chemotherapy for acute myelogenous leukemia. *Ann. Hematol.*, Oct., 71 (4), 161.
-

Schutz U., Munker R., Ertl B., Holler E., and Kolb H.J. (2001): Different types of human leukemias express the message for TNF alpha and interleukin- 10. *Eur. J. Med. Res.*, Aug. 27, 6 (8), 359.

Seishima M., Takemura M., Saito K., Sano H., Minatoguchi S., and Hachiya T. (1996): Highly sensitive ELISA for soluble Fas in serum: increased soluble Fas in the elderly. *Clin. Chem.*, Dec., 42 (12), 1911.

Shalaby M.R., Aggarwal B.B., Rinderknecht E., and Swedersky L.P. (1985): Activation of human polymorphnuclear neutrophil functions by interferon gamma and TNF. *J. Immunol.*, 135, 2069.

Shalaby M.R., Sundan A., Loetscher H., and Espevik T. (1990): Binding and regulation of cellular functions by monoclonal antibodies against human TNF receptors. *J. Exp. Med.*, 172, 1517.

Shu X.O., Gao Y.T., and Linet M.S. (1987): Chloramphenicol use and childhood leukemia in Shanghai. *Lancet*, ii, 934.

Shuman M. (2000): Hemorrhagic disorders: Abnormalities in platelets and vascular function. In *Cecil Textbook of Medicine*, (eds.) by Goldman L. and Bennett J.C., W.B Saunders Company, a division of Harcourt Brace and Company. Philadelphia, London, Toronto, Sydney. 21st edition, chapter 184, page 996.

Sievers E.L. (2000): Clinical studies of new biologic approaches to therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates. *Curr. Opin. Oncol.*, 12 (1), 30.

Silverberg E., and Rubera J.A. (1989): Cancer statistics, CA, 39, 3.

- Simons M., Beinroth S., and Gleichman M. (1999):** Adenovirus mediated gene transfer of inhibitors of apoptosis protein delays apoptosis in cerebellar granule neurons. *J. Neurochem.*, 72, 292.
- Skibber J.M., Matter G.J., and Lotze M.T. (1987):** Right lower quadrant complications in young patients with leukemia. A surgical prospective. *Ann. Surg.*, 206, 711.
- Slevin M.L., Pfall E.M., and Aherne G. (1983):** The effect of dose and schedule on the pharmacokinetic of cytosine arabinoside in plasma and cerebrospinal fluid. *J. Clin. Oncol.*, 1, 9, 546.
- Smith L.J., and Katzenstein A.L.A. (1982):** Pathogenesis of massive pulmonary hemorrhage in acute leukemia. *Arch. Intern. Med.*, 142, 2149.
- Smyth J.F. (1999):** Principles of oncological and palliative care. In Davidson's Principles and Practice of Medicine textbook, (eds.) by Christopher H., Edwin R.C., John A.A., and Nicholas A.B.; Edinburgh, London, New York, Philadelphia, Sydney, Toronto. 18th edition. Chapter 16, page 1054.
- Soares F.A., Landell G.A.M., and Cardoso M.C.M. (1992):** Pulmonary leukostasis without hyperleukocytosis; a clinicopathologic study of 16 cases. *Am. J. Hematol*, 40, 28.
- Specter M.S., Desnoyers S., Hoepfner D.J., and Hengartner M.O. (1997):** Interaction between the C-elegans cell death regulators CED-9 and CED 4. *Nature*, 385, 653.
- Spinelli J.J., Gallagher R.P., and Band R.R. (1984):** Multiple myeloma, leukemia and cancer of the ovary in cosmetologists and hair dressers. *Am. J. Industrial Medicine*, 6, 97.
-

- Stahnke N., and Zisel H.J. (1989):** Growth hormone and leukemia. European J. pediatrics, 148, 591.
- Stass S.A., Mirro J., and Melvin S. (1984):** Lineage switch in acute leukemia. Blood, 94, 701.
- Stephens K.E., Ishizaka A., Larrich J.W., and Raffin T.A. (1988):** TNF increased pulmonary permeability and oedema comparison to septic acute lung injury. Am. Rev. Resp. Dis; 137, 1364.
- Stone R.M., Berg D.T., and George S.L. (1995):** Granulocyte-Macrophage colony stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N. Engl. J. Med., 332, 1671.
- Strieter R., Kunkel S., Showell H., and Marks R. (1995):** The functional role of E-L-R motif in CXC chemokine mediated angiogenesis. J.Biol. Chem., 270, 27348.
- Sugiyama H., Inoue K., and Ogawa H. (1996):** The expression of IL-6 and its related genes in acute leukemia. Leuk. and Lymph., 21, 49.
- Sullivan A.K. (1993):** Classification, pathogenesis, and etiology of neoplastic disease of the hematopoietic system. In Wintrobe's Clinical Hematology (eds.) by Lee G.R., Brithell T., Foerster J., Athens JW. and Lukens J.N., 9th edition. Lea and Fabiger, Philadelphia, page 1725.
- Sultan C., Deregnacourt J., and Ko Y.W. (1981):** Distribution of 250 cases of acute myeloid leukemia according to the FAB classification and response to therapy. Br. J. Haematol., 47, 545.
-

- Swansburg G.J., Lawler S.D., Alimena G., and Arthr D. (1994):** Long-term Survival in acute myelogenous leukemia. A second follow up of the fourth International Workshop on chromosome in leukemia. *Cancer Genet. Cytogenet.*, 73, (supple 1), 1.
- Tallman M.S., Hakiman D., and Show J.M. (1993):** Granulocytic sarcoma is associated with the 8 ; 21 translocation in acute myeloid leukemia . *J. Clin. Oncol.*, 11 , 690.
- Tamura S., and Kanamaru A. (1995):** De novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) and myelodysplastic remission marrow (AML/MRM). *Leuk-Lymphoma*, 16,263.
- Tanner J.E., and Tosato G. (1992):** Regulation of B-cell growth and immunoglobulin gene transcription by IL-6. *Blood*, 79, (2), 452.
- Thomas X., Hirschauer C., Troncy J., and Assouline D. (1997):** Complex effects of interleukin 6 on clonogenic blast cell growth in acute myeloblastic leukemia. *Acta Haematol.*, 98 (1), 14.
- Thornberry N.A., and Lazebnik Y. (1998):** Caspases enemies within. *Science*, 281, 1312.
- Tobelem G., Jacquillat C., and Chastang C. (1980):** Acute monoblastic leukemia. A clinical and biologic study of 74 cases. *Blood*, 55, 71.
- Tobler A., Moser B., Dewald B., Geiser T., Studer H., and Fey M.F. (1993):** Constitutive expression of interleukine-8 and its receptor in human myeloid and lymphoid leukemia. *Blood*, oct. 15, 82 (8), 2517.
-

- Tothova E., Elbertova A., Fricova M., Kafkova A., Stecova N., and Raffac S. (2001):** P-glycoprotein expression in adult acute myeloid leukemia; correlation with induction treatment outcome. *Neoplasma*, 48, (5), 393.
- Tracey K.J., Beutler B., and Lowry S.F. (1986):** Shock and tissue injury induced by recombinant human cachectin. *Science*, 234, 470.
- Trentin L., Zambelle R., Agostini C., Pizzolo G., and Semenzato G. (1993):** Expression and function role of tumor necrosis factor receptors of leukemic cells from patients with type B chronic lymphoproliferative disorders. *Blood*, 81, 752.
- Tsimberidou A.M., and Giles F.G. (2002):** TNF- α targeted therapeutic approaches in patients with hematologic malignancies. *Expert. Rev. Anticancer Ther.*, Jun; 2 (3), 277.
- Tucker J., Amess J.A.L., and Gregory W.M. (1990):** Acute myeloid leukemia in elderly adults. *Haematol., Oncol.*, 8, 13.
- Tushar P. (2000):** Apoptosis in hepatic pathophysiology. *Clinics in liver disease* , 4 (2), 295.
- Urowitz M.D., and Rider W.D. (1985):** Myeloproliferative disorders in patients with rheumatoid arthritis treated with total body irradiation. *Am. J. med.*, 78, (suppl. 1A), 50 .
- Van Buchem M.E., Wondergem J.H., and Kool L.J.S. (1987):** Pulmonary leucocytosis. Radiologic pathologic study. *Radiology*, 165, 739.
-

- Van Damme J., and Apdenakker G. (1991) :** Interaction of interferons with skin reactive cytokines from interleukin-1 to interleukin-8. *J. Invest. Dermatol.*, 95 (6), 90.
- Verheij M., Van Blitterswijk W.J., and Bartelink H. (1998):** Radiation-induced apoptosis. The ceramide SAPK signaling pathway and clinical aspects. *Acta. Oncol.*, 37, 575.
- Vinante F., Rigo A., Vincenzi C., Ricetti M.M., and Pizzolo G. (1993) :** IL-8 mRNA expression and IL-8 production by acute myeloid leukemia cells. *Leukemia*, Oct., 7 (10), 1552.
- Wallace R.R., and Lowe S.W. (1999) :** Clinical implication of P53 mutations . *Cell Molec. Life . Science*, 55, 64.
- Wang A.M., Greasy A.A., Lander M.B., and Lin L.S. (1985):** Molecular cloning of the complementary DNA for human TNF. *Science*, 228, 149.
- Wang H.G., Pathan N., and Ethell I.M. (1999):** Ca^{++} - induced apoptosis through calcineurin dephosphorylation of BAD. *Science*, 284, 339.
- Weidmann E., Brieger J., Karakas T., Maurer U., and Pascheberg W. (1997):** Establishment and characterization of a new factor independent acute myeloid leukemia line designated Ei 501. *leukemia*, 11, 709.
- Weik J., Kopecky K., and Applebaum F. (1992):** A randomized investigation of high dose (HDAC) versus standard dose (SDAC) cytosine arabinoside with daunorubicin (DNR) in patients with AML. *Proc. Am. Soc. Clin. Oncol.*, 11 , 856.
-

- Weil M., Jacquillat C., and Gemon-Aucherc M.F. (1976):** Acute granulocytic leukemia; treatment of the disease. *Arch. Intern. Med.*, 136, 1389.
- Weirnik P.H. (1982):** Acute leukemias of adults. In *Cancer Principles and Practice of Oncology* (eds.) by Devita V.T., Hellman S. and Rosenberg A.A., J.B. Lippincott Co., Philadelphia, page 1402.
- Westerman F., Kube D., Haier B., Bohlen H., Engert A., and Tesch H. (1996):** Interleukin-10 inhibits cytokine production of human AML cells. *Ann. Oncol.* Apr., 7 (4), 397.
- Whelan J.S., Davis C.L., and Leahy M. (1992):** Etoposide in combination with intermediate cytosine arabinoside given with the intention of further myeloablative therapy for the treatment of refractory or recurrent hematological malignancy. *Haematol. Oncol.*, 10, 87.
- White M.K., and Mc Cubrey J.A. (2001):** Suppression of apoptosis; role in cell growth and neoplasia. *Leukemia*, 15, 1011.
- Widmann C., Gibson S., and Johnson G.L. (1998):** Caspase dependent cleavage of signaling proteins during apoptosis. A turn off mechanism for anti-apoptotic signals. *J. Biol. Chem.*, 273, 7141.
- Wiernik P.H. (1996):** Diagnosis and treatment of adult acute myelocytic leukemia. In *Neoplastic diseases of the blood*, (eds.) by Wiernik P.H., Canollos G.P., Dutcher J.P. and Kyle R.A., Churchill livingstone, New York, Edinburgh, London, Madrid, Melbourne, San Francisco, and Tokyo. 3rd edition, page 331.
-

- Wilson H.E., Bodey G.P., and Moon T.E. (1977):** Adriamycin therapy in previously treated adult acute leukemia. *Cancer treat. Rep.*, 16, 905.
- Worsley A., Oscier D.G., and Stevens J. (1988):** Prognostic features of chronic myelomonocytic leukemia, a modified buernemouth score gives the best prediction of survival. *Br. J. Haematol*, 68, 17.
- Wulf G.G., Jahns S.G., Hemmerlein B., and Bonneken K. (1998):** Plasmacytosis in acute myeloid leukemia: two cases of plasmacytosis and increased IL-6 production in the AML blast cells. *Ann. Hematol.*, Jun, 76 (6), 273.
- Wyllie A.H. (1997):** Apoptosis: an overview. *Br. Med. Bull*, 53, 451.
- Wyllie A.H., Bellamy C.O., Bubb V.J., Clarke A.R., Corbet S., and Curtis L. (1999):** Apoptosis and carcinogenesis. *Br. J. Cancer* , 80 (suppl 1), 34.
- Yam L.T., Lic Y., and Crosby W.H. (1971):** Cytochemical identification of monocytes and granulocytes. *Am. J. clin. Pathol.*, 55 , 283.
- Yamagushi H., Inokushi K., and Dan K. (2002):** The study for loss of bcl-xs expression as a prognostic factor in acute myeloid leukemia. *Leuk. Res.*, Dec., 26 (12), 1119.
- Yang Y., Fang S., Jensen J.P., and Weissman A.M. (2000):** Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. *Science*, 288, 874.
-

- Yang Y., Liu X., and Bhalla K. (1997):** Prevention of apoptosis by Bcl-2, release of cytochrome C from mitochondria blocked. *Science*, 275, 1129.
- Yokel B.K., Friedman K.J., and Farmer E.R. (1987):** Cutaneous pathology following etoposide therapy. *J. Cutaneous pathol.*, 14, 326.
- Young C.C., Ozols C.F., and Myers C.E. (1981):** The anthracycline anti-neoplastic drugs. *New Engl. J. of Medicine*, 305, 139.
- Yuan J. (1996):** Evolutionary conservation of a genetic pathway of programmed cell death. *J. cell. Biochemi.*, 60, 4.
- Yunis J.J., Bloopfield C.D., and Ensrud K. (1981):** All patients with acute non-lymphocytic leukemia may have a chromosomal defect. *N. Engl. J. Med.*, 305, 135.
- Zhang H., D'Arpe P., and Liu L.F. (1990):** A model for tumor cell killing by topoisomerase poisons. *Cancer cells*, 2, 23.
- Zhou J., Chen Y., and Li C. (1997):** Ara-C induced apoptosis in human myeloid leukemia cell line HL60. *Chung-Hua-Chung-Liu-Tsa-Chih*, Mar., 19 (2), 107.
- Zittoun R.A., Mandelli E., and Willemze R. (1995):** Autologous or allogenic bone marrow transplantation compared with intensive chemotherapy in AML. *N. Engl. J. Med.*, 232, 217.
- Zou H., Henzol W.J., and Liu X. (1997):** Apaf-1, a human protein homologues to C-elegans CED-4, participates in cytochrome C dependent activation of caspase-3. *Cell*, 90, 405.
-

Zwann F.E., and Herman J. (1983) : Report of the E.M.B.T. leukemia
working party. Exp. Haematol., 11, 3.
